Latest Breaking News On - Astellas venture management - Page 3 : comparemela.com

Astellas Venture Management and MBC BioLabs Announce the 5th Annual Astellas Future Innovator Prize

/PRNewswire/ Astellas Venture Management LLC (President: William Watt, Ph.D., "AVM"), a wholly owned venture capital subsidiary of Astellas Pharma Inc..

Mission bayUnited statesSan franciscoSan carlosDouglas crawfordNaoki okamuraWilliam wattAstellas pharma incAstellas venture managementPrnewswire astellas venture managementMission biocapitalAstellas pharmaAstellas future innovatorBay areaBespoke therapeuticsAstellas future innovator prize

Astellas Venture Management and MBC BioLabs Announce the 5th Annual Astellas Future Innovator Prize

Astellas Venture Management and MBC BioLabs Announce the 5th Annual Astellas Future Innovator Prize
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

San carlosUnited statesMission baySan franciscoWilliam wattDouglas crawfordNaoki okamuraAstellas pharma incPrnewswire astellas venture managementMission biocapitalAstellas venture managementAstellas pharmaAstellas future innovatorBay areaBespoke therapeuticsAstellas future innovator prize

Solu Therapeutics Launches with $31 Million to Unlock Cell-Surface Targets

Solu Therapeutics Launches with $31 Million to Unlock Cell-Surface Targets
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.

United statesAl iskandariyahChristoph westphalSatoshi konagaiOmar khalilJohn hamerDavid donabedianPeter huttBrandon turunenLongwood fundSolu therapeuticsCytotoxicity targeting chimeraAstellas venture managementAlexandria venture

Solu Therapeutics raises funds to develop CyTaC platform and drugs

Solu Therapeutics has raised $31m in seed financing to develop the Cytotoxicity Targeting Chimera (CyTaC) platform and drug candidates.

Al iskandariyahPeter huttJohn hamerDavid donabedianSatoshi konagaiOmar khalilChristoph westphalLongwood fundAlexandria venture investmentsAstellas venture managementTherapeutic cytacSolu therapeutics

Solu Therapeutics Raises $31M in Seed Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Al iskandariyahUnited statesJohn hamerOmar khalilDavid donabedianSatoshi konagaiPeter huttChristoph westphalLongwood fundSolu therapeuticsAstellas venture managementAlexandria ventureCytotoxicity targeting chimeraFounding executive chairmanFounding partnerManaging director